Indeed, mass spectrometry analysis, pull down assay and the synthesis of pDnmt1S127 and pDnmt1S143 antibodies validated the fact that these two kinases play a crucial role in the formation/disruption of the Dnmt1-PCNA-UHRF1 interactions and suggest that the use of these antibodies could be used as an alternative predictor of disease outcome since the high level of pDnmt1S127 and pDnmt1S143 in GBM seems to be associated with a poor prognosis factor of survival. The gene discussed is DNMT1; the disease is glioblastoma.